Advanced search
Publication Cover
Expert Review of Endocrinology & Metabolism Volume 8, 2013 - Issue 6
Submit an article Journal homepage
39
Views
0
CrossRef citations to date
0
Altmetric
Reviews

Pituitary incidentalomas: application of an evidence-based approach at the individual patient and population levels

David C AronLouis Stokes Cleveland Department of Veterans Affairs Medical Center, Interprofessional Implementation Research, Evaluation and Clinical Center, Medicine and Epidemiology and Biostatistics, School of Medicine, Cleveland, 14(W), 10701 East Boulevard, Cleveland, OH 44106, USA and;Department of Organizational Behavior, Case Western Reserve University Weatherhead School of Management, 14(W), 10701 East Boulevard, Cleveland, OH, USACorrespondence[email protected]
[email protected]
Pages 517-527 | Published online: 10 Jan 2014

References

  • Abdelmannan D, Aron DC. Incidentally-discovered pituitary masses: pituitary incidentalomas. Expert Rev. Endocrinol. Metabl. 5, 2 253–264 (2010).
  • Fernández-Balsells MM, Murad MH Barwise A et al. Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 96, 4 905–912 (2011).
  • Nammour G. Ybarra J, Naheedy M, Romeo J, Aron D. Incidental pituitary macroadenoma: a population-based study. Am. J. Med. Sci. 314, 287–291 (1997).
  • Freda P. Post K. Differential diagnosis of sellar masses. Endocrinol. Metab. Clin.North. Am 28, 81–117 (1995).
  • Raghavan P. Phillips C. Evidence-based neuroimaging diagnosis and treatment. Springer New York, USA, 459–470 (2013).
  • Shah S, Waldman AD. Mehta A. Advances in pituitary imaging technology and future prospects. Best Pract. Res. Clin. Endocrinol. Metab. 26, 1 35–46 (2012).
  • Hyun SH, Choi JY, Lee KH, Choe YS, Kim BT. Incidental focal 18F-FDG uptake in the pituitary gland: clinical significance and differential diagnostic criteria. J. Nucl. Med. 52, 4 547–550 (2011).
  • Jeong SY, Lee SW. Lee HJ et al. Incidental pituitary uptake on whole-body 18F-FDG PET/CT: a multicentre study. Eur. J. Nucl. Med. Mol. Imaging 37, 12 2334–2343 (2010).
  • Tiktinsky E. Horne T, Friger M, Agranovich S, Lantsberg S. Pituitary incidentalomas detected with technetium-99 m MIBI in patients with suspected parathyroid adenoma: preliminary results. World J. Nucl. Med. 11, 1 3–6 (2012).
  • Howlett TA, Como J, Aron DC. Management of pituitary incidentalomas. A survey of British and American endocrinologists. Endocrinol. Metab. Clin. North. Am 29, 223–230 (2000).
  • Freda P. Beckers A, Katznelson L et al. Pituitary incidentaloma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 4 894–904 (2011).
  • Lania A. Beck-Peccoz P. Pituitary incidentalomas. Best Pract. Res. Clin. Endocrinol. Metab. 26, 4 395–403 (2012).
  • Marko N. Weil R. Management of incidental pituitary tumors. Oncol. Rev. 5, 4 233–239 (2011).
  • Mavrakis A. Tritos N. Diagnostic and therapeutic approach to pituitary incidentalomas. Endocr. Pract. 10, 438–444 (2004).
  • Molitch M. Non-functioning pituitary tumors and pituitary incidentalomas. Endocrinol. Metab. Clin. North Am 37, 151–171 (2008).
  • Vassiliadi DA. Tsagarakis S. Endocrine incidentalomas–challenges imposed by incidentally discovered lesions. Nat. Rev. Endocrinol. 7, 11 668–680 (2011).
  • Newell-Price J. Whither pituitary incidentaloma? J. Clin. Endocrinol. Metab. 96, 4 939–941 (2011).
  • Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence-based medicine: what it is and what it isn’t. Br. Med. J. 312, 71–72 (1996).
  • Anagnostis P. Adamidou F, Polyzos SA, Efstathiadou Z, Panagiotou A, Kita M. Non-functioning pituitary adenomas: a single center experience. Exp. Clin. Endocrinol. Diabetes 119, 5 314–319 (2011).
  • Gruppetta M. Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in malta. Pituitary doi:10.1007/s11102-012-0454-0 (2012) (Epub ahead of print).
  • Levy MJ. The association of pituitary tumors and headache. Curr. Neurol. Neurosci. Rep. 11, 2 164–170 (2011).
  • Onnestam L. Berinder K, Burman P et al. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. J. Clin. Endocrinol. Metab. 98, 2 626–635 (2013).
  • Holmer HK, Ogden LA, Burda BU, Norris SL. Quality of clinical practice guidelines for glycemic control in type 2 diabetes mellitus. PLoS ONE 8(4), e58625 (2013).
  • Aron DC. Evidence-based endocrinology & clinical epidemiology. In: Gardner D, Shoback D, (Eds). Greenspan’s Basic and Clinical Endocrinology. McGraw Hill, New York (2011).
  • Atkins D. Best D, Briss PA et al. Grading quality of evidence and strength of recommendations. BMJ 312, 71–72 (1996).
  • Schunemann HJ. Jaeschke R, Cook DJet al. An official ATS statement: grading the quality of evidence and strength of recommendations in ATS guidelines and recommendations. Am. J. Respir. Crit. Care Med. 174(605), 614 (2006).
  • Swiglo BA, Murad MH. Schünemann HJet al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J. Clin. Endocrinol. Metab. 93, 3 666–673 (2008).
  • Fainstein DP. Guitelman M, Artese Ret al. Retrospective multicentric study of pituitary incidentalomas. Pituitary 7, 3 145–148 (2004).
  • Bex M. Abs R, T’Sjoen Get al. AcroBel–the Belgian registry on acromegaly: a survey of the ’real-life’ outcome in 418 acromegalic subjects. Eur. J. Endocrinol. 157, 4 399–409 (2007).
  • Ciccarelli A, Daly AF. Beckers A. The epidemiology of prolactinomas. Pituitary 8, 1 3–6 (2005).
  • Fernandez A. Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshir, UK). Clin. Endoccrinol. (Oxf.) 312, 71–72 (1996).
  • Mestron A, Webb SM. Astorga Ret al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA). Eur. J. Endocrinol. 151, 4 439–446 (2004).
  • Raappana A. Koivukangas J, Ebeling T, Pirila T. Incidence of pituitary adenomas in Northern Finland in 1992–2007. J. Clin. Endocrinol. Metab. 95, 9 4268–4275 (2010).
  • Ritchie CM, Atkinson AB. Kennedy ALet al. Ascertainment and natural history of treated acromegaly in Northern Ireland. Ulster. Med. J. 59, 1 55–62 (1990).
  • Steffensen C, Bak AM, Rubeck KZ, Jorgensen JO. Epidemiology of Cushing’s syndrome. Neuroendocrinology 92(Suppl. 1), 1–5 (2010).
  • Borenstein R. Katz Z, Lancet M, Caspi B, Ben-David M. Bromocriptine treatment of hyperprolactinemic infertility with ovulatory disturbances. Int. J. Gynaecol. Obstet. 18, 3 195–199 (1980).
  • Cooper O. Ben-Shlomo A, Bonert V, Bannykh S, Mirocha J, Melmed S. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm. Cancer 1, 2 80–92 (2010).
  • Klibanski A, Zervas NT, Kovacs K, Ridgway EC. Clinically silent hypersecretion of growth hormone in patients with pituitary tumors. J. Neurosurg. 66, 6 806–811 (1987).
  • Sakharova A. Dimaraki E, Chandler W, ALB. Clinically silent somatotropinomas may be biochemically active. J. Clin. Endocrinol. Metab. 312, 71–72 (1996).
  • Wade AN, Baccon J, Grady MS, Judy KD, O’Rourke DM,Snyder PJ. Clinically silent somatotroph adenomas are common. Eur. J. Endocrinol. 165, 1 39–44 (2011).
  • Ribeiro-Oliveira AJr., Barkan A. The changing face of acromegaly–advances in diagnosis and treatment. Nat. Rev. Endocrinol. 8, 10 605–611 (2012).
  • Yuen KCJ,Cook DM. Sahasranam Pet al. Prevalence of GH and other anterior pituitary hormone deficiencies in adults with nonsecreting pituitary microadenomas and normal serum IGF-1 levels. Clin. Endoccrinol. (Oxf.) 69, 2 292–298 (2008).
  • Dekkers OM. Hammer S, de Keizer RJet al. The natural course of non-functioning pituitary macroadenomas. Eur. J. Endocrinol. 156, 2 217–224 (2007).
  • Oyama K. Sanno N, Tahara S, Teramot A. Management of pituitary incidentalomas: according to a survey of pituitary incidentalomas in Japan. Semin. Ultrasound CT MR 312, 71–72 (1996).
  • Tabarin A. Perez P. Pros and cons of screening for occult Cushing syndrome. Nat. Rev. Endocrinol. 7, 8 445–455 (2011).
  • Feldkamp J. et al. Incidentally discovered pituitary lesions: high frequency of macroadenomas and hormone-secreting adenomas - results of a prospective study. Clin. Endoccrinol. (Oxf.) 312, 71–72 (1996).
  • Gibney J. Smith T, TJM. Clinical relevance of macroprolactiemia. Clin. Endoccrinol. (Oxf.) 312, 71–72 (1996).
  • Molitch M. Medication-induced hyperprolactinemia. Mayo Clin. Proc. 312, 71–72 (1996).
  • Mulligan T, Frick MF, Zuraw QC. Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int. J. Clin. Pract. 60, 7 762–769 (2006).
  • Welch H. Schwartz L, Woloshin S. Overdiagnosed: Making People Sick in the Pursuit of Health. Beacon, Boston (2011).
  • Hall WA, Luciano MG, Doppman JL, Patronas NJ, Oldfield EH. Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population. Ann. Intern. Med. 312, 71–72 (1996).
  • King JT Jr,Justice A, Aron DC. Management of incidental pituitary macroadenomas: a cost-effectiveness analysis. J. Clin. Endocrinol. Metab. 82, 82 3625–3632 (1997).
  • Randall BR, Kraus KL, Simard MF, Couldwell WT. Cost of evaluation of patients with pituitary incidentaloma. Pituitary 13, 4 383–384 (2010).
  • Brenner DJ, Hall EJ. Computed tomography–an increasing source of radiation exposure. N. Engl. J. Med. 357, 22 2277–2284 (2007).
  • Cawood TJ, Hunt PJ, O’Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur. J. Endocrinol. 161, 4 513–527 (2009).
  • Mold JW, Stein HF. The cascade effect in the clinical care of patients. N. Engl. J. Med. 314, 8 512–514 (1986).
  • Sox HC, Goodman SN. The methods of comparative effectiveness research. Annu. Rev. Public Health 312, 71–72 (1996).
  • Clarke A. Shim J, Mamo Let al. Biomedicalization: technoscientific transformations of health, illness and U.S. biomedicine. Am. Sociol. Rev. 68, 2 161–194 (2003).
  • Joyce K. The development of magnetic resonance imaging and the visual turn in medicine. Sci. Cul. 15, 1 1–22 (2006).
  • Moynihan R. Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ 344, e3502 (2012).
  • Moynihan R. Glasziou P, Woloshin S, Schwartz L, Santa J, Godlee F. Winding back the harms of too much medicine. BMJ 346, f1271 (2013).
  • Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 301, 8 831–841 (2009).
  • Wagner J, Aron DC. Incidentalomas: a “disease” of modern imaging technology. Best Pract. Res. Clin. Endocrinol. Metab. 26(1), 3–8 (2012).
  • Morin SH, Cobbold JF. Lim AKet al. Incidental findings in healthy control research subjects using whole-body MRI. Eur. J. Radiol. 72, 3 529–533 (2009).
  • Orme NM, Fletcher JG. Siddiki HAet al. Incidental findings in imaging research: evaluating incidence, benefit, and burden. Arch. Intern. Med. 170, 17 1525–1532 (2010).
  • Wolf SM, Lawrenz FP. Nelson CAet al. Managing incidental findings in human subjects research: analysis and recommendations. J. Law Med. Ethics 36(2), 219–48, 211 (2008).
  • Volk M. Ubel P. Better Off Not Knowing: Improving Clinical Care by Limiting Physician Access to Unsolicited Diagnostic Information. Arch. Intern. Med. 171, 6 487–488 (2011).
  • Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA 307, 17 1801–1802 (2012).
  • Schwartz KL, Roe T, Northrup J, Meza J, Seifeldin R, Neale AV. Family medicine patients’ use of the internet for health information: a metronet study. J. Am. Board. Fam. Med. 312, 71–72 (1996).
  • Molitch ME. Clinical review 65. Evaluation and treatment of the patient with a pituitary incidentaloma. J. clin. Endocrinol. Metab. 80, 1 3–6 (1995).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.